Wize Pharma and Cosmos Capital enter into Bid Implementation Agreement
USA - English
- Cosmos Capital, a digital infrastructure provider, to become publicly traded through a business combination with Wize
- The combined company is expected to have approximately US$5 million in cash and cash equivalents at closing
News provided by
Share this article
HOD HASHARON, Israel, and SYDNEY, Dec. 30, 2020 /PRNewswire/ --
Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and Cosmos Capital Limited, a leading digital infrastructure provider based in Sydney, Australia, today announced that they have entered into a bid implementation agreement ("BIA"), whereby Wize has agreed to make an off-market takeover offer to acquire all of the outstanding shares of Cosmos, subject to satisfaction of various closing conditions set forth in the BIA, resulting in Cosmos becoming a wholly-owned subsidiary of Wize.